Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - ADVENTRX Pharmaceuticals, Inc. (ANX-NYSE Amex) |
|
|
“ADVENTRX stands out among its small cap peers because we expect to submit an NDA, the final regulatory hurdle to drug approval, this year. There is only a limited amount of work remaining before we submit that NDA, and we have both the financial and human capital to get there.” - Brian M. Culley, M.A., M.B.A. (ANX) (Interview published June 18, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
ADVENTRX Pharmaceuticals to Present at The
Rodman & Renshaw Annual Global Investment Conference on September 14
SAN DIEGO, Sept 01, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday September 14, 2010 at 11:40 a.m. Eastern time, in the Hubbard Salon at the New York Palace Hotel in New York. Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals website at http://www.adventrx.com/. An archived presentation will be available on the website for 30 days. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's website at http://www.adventrx.com/. SOURCE ADVENTRX Pharmaceuticals, Inc.
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.